AMENDMENT NO. 1 TO SCHEDULE 13D

Company

GYRE THERAPEUTICS, INC.

Filed

February 10, 2015

Accession Number

0000921895-15-000248

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →